Multitargeted therapies for multiple myeloma
Copyright policy )Multitargeted therapies for multiple myeloma
Multiple myeloma (MM) comprises 1% of all malignancies and 10% of all hematological malignancies. MM is a malignancy of plasma cells in the bone marrow where complex and dynamic interactions with the bone marrow microenvironment lead to tumor progression, skeletal destruction and angiogenesis. Despite the discovery of several novel treatments against MM, including the proteasome inhibitor bortezomib, it is considered to be an incurable disease with an average 4-5 years overall survival.
- Karolinska Institute Sweden
Niacinamide, Phenylurea Compounds, Sorafenib, Models, Biological, Disease Models, Animal, Mice, Proto-Oncogene Proteins c-bcl-2, Animals, Humans, Molecular Targeted Therapy, Multiple Myeloma
Niacinamide, Phenylurea Compounds, Sorafenib, Models, Biological, Disease Models, Animal, Mice, Proto-Oncogene Proteins c-bcl-2, Animals, Humans, Molecular Targeted Therapy, Multiple Myeloma
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).5 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!